ARTICLE | Clinical News
Idec begins Phase II in psoriasis
January 11, 2001 8:00 AM UTC
IDPH began a placebo-controlled, dose-escalation Phase II trial of IDEC-114, its primatized anti- CD80 monoclonal antibody, to treat moderate to severe psoriasis. ...